Trials / Available
AvailableNCT06707480
Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
Expanded Access Program to Provide Access to Defencath® for Adult and Pediatric Patients Using a Catheter to Prevent Central Line-Associated Bloodstream Infections (CLABSIs)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- CorMedix · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The EAP for DefenCath is designed to provide access to a broader population of adult and pediatric patients using catheters for various serious medical conditions. A key aspect of this EAP is its focus on individuals who, due to their unique clinical circumstances, are either ineligible for participation in ongoing clinical trials or do not meet the criteria outlined in the current approved FDA label for DefenCath.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Taurolidine and Heparin | Catheter Lock Solution |
Timeline
- First posted
- 2024-11-27
- Last updated
- 2024-11-27
Source: ClinicalTrials.gov record NCT06707480. Inclusion in this directory is not an endorsement.